Premium
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis
Author(s) -
Berger Joseph R.,
Centonze Diego,
Comi Giancarlo,
Confavreux Christian,
Cutter Gary,
Giovani Gavin,
Gold Ralf,
Hartung HansPeter,
Lublin Fred,
Miravalle Augusto,
Montalban Xavier,
O'Connor Paul,
Olsson Tomas,
Polman Chris H.,
Stuve Olaf,
Wolinsky Jerry S.,
Ziemssen Tjalf
Publication year - 2010
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22083
Subject(s) - neurology , medicine , clinical neurology , natalizumab , annals , multiple sclerosis , psychology , classics , psychiatry , history , neuroscience
Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis Joseph R. Berger, MD, Diego Centonze, MD, Giancarlo Comi, MD, Christian Confavreux, MD, Gary Cutter, PhD, Gavin Giovannoni, MD, Ralf Gold, MD, Hans-Peter Hartung, MD, Fred Lublin, MD, Augusto Miravalle, MD, Xavier Montalban, MD, Paul O’Connor, MD, Tomas Olsson, MD, PhD, Chris H. Polman, MD, Olaf Stuve, MD, PhD, Jerry S. Wolinsky, MD, and Tjalf Ziemssen, MD